Pharmaceutical New Development 2010

• Publication date: March 2010

About This Report Pharma faces a number of key resistors to growth including the impending 2011 patent cliff which is set to erode USD 78 billion in global branded sales from drugs facing patent expiry over the 201014 period (plus USD 32 billion from continued erosion of already expired brands). Price cuts, reimbursement restrictions and growing regulatory pressure are further set to limit sales growth going forward. What...

About This Report

Pharma faces a number of key resistors to growth including the impending 2011 patent cliff which is set to erode USD 78 billion in global branded sales from drugs facing patent expiry over the 201014 period (plus USD 32 billion from continued erosion of already expired brands). Price cuts, reimbursement restrictions and growing regulatory pressure are further set to limit sales growth going forward.

What's In This Report


* Overview of the key drivers and resistors facing Pharma, Biotech and generic drugs players out to 2014

* Analysis of recent regulatory changes in the US, EU and emerging industry s and their impact on pricing and reimbursement, drug development and industry ing

* Examination of key global and country-specific issues facing both biosimilars and generic drugs players

* Assessment of the impact of the global economic downturn on the Pharma and Biotech segments and their respective counter strategies

Key Market Facts

Annual sales growth of pharmaceuticals in the emerging industry s is already double-digit, providing a key opportunity for Pharma. Revenue streams in these industry s can be derived from launching branded off-patent drugs, branded generic drugs, and local brands owned or licensed by the acquiring pharma firm .

Pharma is moving away from the "me-too" and increasingly genericized primary care industry towards more high value biologic therapies in secondary care as well as more niche industry s; industry s with little or no existing competition, and which despite their smaller size (in terms of patient numbers) are still commercially attractive.

To maintain profitability in the face of slowing sales to 2014, pharma industry players have implemented a number of cost-cutting measures (in addition to strategic repositioning and diversification strategies) in order to boost profitability going forward.

Why Should You Buy This Report?


* Examine the combined prescription drug revenue projections for the top 50 Pharma out to 2014 by molecule type, product source, geography and therapy area

* Identify the key factors impacting Pharma's Research and Development productivity as well as the solutions industry players are implementing to strengthen their Research and Development efforts

* Assess key drivers behind Pharma's Merger and Acquisition activity and its role in boosting profits by opening up new access to new industry s as well as cutting costs

Pharmaceutical Industry in China

ABOUT DATAMONITOR HEALTHCARE 2
About the Healthcare Strategic Analysis Team 2
1. About this report 3
Data sourcing – the PharmaVitae Explorer database 3
Chapter structure 4
Glossary 5
Related reports 5
Upcoming related reports 5
2. Summary 6
Key drivers and resistors facing Pharma 6
Resistors for Pharma 7
Drivers for Pharma 14
Neutral for Pharma 23
Key drivers and resistors facing generics drugs and biosimilars industry players 26
Key drivers and resistors facing Biotech 28
3. Healthcare Systems and Regulations 32
Expansion of healthcare provision top of the agenda of many countries 32
US health reform set to change the country’s healthcare landscape 36
The FDA is set on restoring its reputation 62
Drug prices suffer in Japan 69
Five major EU industry s – cost-containment pressures mount 72
EU legislation focused on streamlining regulatory processes 80
New healthcare initiatives in the emerging industry s are tackling growing costs 83
Brazil’s ANVISA may hamper the domestics growth of multinational pharma industry players 85
Russia enhances regulations to boost growth of the domestic pharma market 87
India tackles growing healthcare spending by tightening price controls and increasing access to generic drugs 90
China’s healthcare reforms will grow the domestic industry but may create challenges for foreign industry players 92
4. Generic Drugs and Biosimilars 95
The generics drugs industry 96
The biosimilars industry 117
5. Recession and Recovery 131
Appendix
Pharmaceutical Key Drivers and Main Trends 2010 DMHC2599
Largely insulated from the recession Pharma’s key threat is the patent cliff 131
Biotech emerges from its funding crisis 138
6. Prescription Drug Industry Outlook 146
Definitions – launch, core, expiry 146
Drivers and resistors for sales growth of the top 50 pharma industry players out to 2014 146
7. Research and Development 164
Pharma continues to battle with Research and Development issues 164
Pharma’s Research and Development cost-cutting exercise is only a short-term solution 168
Pharma’s late-stage deal activity set to increase to help offset the patent cliff 170
Pharma’s level of early-stage Research and Development collaboration intensifies 171
Outsourcing set to rise following initial cost-cutting exercises implemented during the economic downturn 173
Pharma sharpens its focus on secondary care indications through high value biologic therapies as the patent cliff looms 175
Personalized medicine and stem cell technology are key strategies in the commercialization of niche indications 183
Pharma embraces low cost late-stage lifecycle management strategies 187
8. Mergers and Acquisitions 192
M&A will remain a central strategy for Pharma 192
Merger and Acquisition to increase scale and cut costs 196
Merger and Acquisition to target high growth therapeutic industry s 199
Merger and Acquisition to target high growth geographic industry s 201
Merger and Acquisition to increase pharma focus or diversify into other healthcare industry s 205
9. Bibliography 212
Summary 212
Healthcare Systems and Regulations 212
Generic Drugs and Biosimilars 223
Recession and Rrecovery 232
Prescription Drug Industry Outlook 235
Research and Development 235
Mergers and Acquisitions 241
APPENDIX 244
Exchange rates 244
US healthcare reform model 245
About Datamonitor 253
Appendix
Datamonitor consulting 254
Disclaimer 256

Pharmaceutical in China

China Poisonings, 30-44 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : China

China Poisonings, 60-69 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : China

China Poisonings, 5-14 Yrs, Female, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : China

China Poisonings, 30-44 Yrs, Female, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : China

China Poisonings, 60-69 Yrs, Female, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pharmaceutical
• Countries : China